Supplementary Experimental Section

SE. 1. NMR Experiments.
General. Nuclear Magnetic Resonance (NMR) spectra were recorded with a Bruker AVIII 600 MHz NMR spectrometer equipped with a BB- 19 F/ 1 H Prodigy N 2 cryoprobe using 5 mm diameter NMR tubes (Norell). Data were processed with Bruker 3.1 software.
H Excitation Sculpting Suppression NMR Experiments. For H excitation sculpting
suppression NMR experiments, spectra were typically obtained using 16 scans and a relaxation delay of 1 s. A 2 ms Sinc pulse was used for water suppression. The assay mixture contained 20 µM di-Zn(II)-VIM-5 or apo-VIM-5 supplemented with 400 µM of the compound to be studied buffered with 50 mM Tris-D 11 wLOGSY NMR experiments. water-Ligand Observed Gradient SpectroscopY (wLOGSY) experiments were conducted using the pulse sequence described by Dalvit et al. 1 Typical experimental parameters were as follows: mixing time, 1 s; relaxation delay, 2 s; number of transients, 400. Solvent excitation was achieved using a 16 ms 180 degree selective rectangular shape pulse with 1000 points (Squa100.1000) set at the H 2 O frequency. Water suppression was achieved by a 2 ms Sinc pulse (Sinc1.1000) pulse at the H 2 O frequency. The assay mixture contained 20 µM di-Zn(II)-VIM-5 or apo-VIM-5 supplemented with 400 µM of the compound to be studied buffered with 50 mM Tris-D 11 (pH 7.5) and 0.02 % NaN 3 in 90 % H 2 O and 10 % D 2 O. 1 H CPMG NMR experiments. Typical experimental parameters for Carr-Purcell-Meiboom-Gill (CPMG) NMR spectroscopy were as follows: total echo time, 40 ms; relaxation delay, 2 s; number of transients, 128. The PROJECT-CPMG sequence (90°x−[τ−180°y−τ−90°y−τ−180°y−τ] n−acq) as described by Aguilar et al 2 was applied. Water suppression was achieved by pre-saturation. Data were processed with Bruker 3.1 software. Prior to Fourier transformation, data were multiplied with an exponential function with a 0.3-Hz line broadening. Titrations were carried out and dissociation constant (K D ) values fitted as reported 3 .
SE. 2. Chemical Synthesis.
All chemicals including reagents and solvents were from Sigma-Aldrich (Dorset, U.K.) and used without further purification. Solvents used were of HPLC purity and used for reactions chromatography and work-ups. Aqueous solutions were made using deionized water. Thin layer chromatography (TLC) was carried out using Merck (Darmstadt, Germany) silica gel 60 F254 TLC plates. TLC visualization was carried out under UV light, and stained with one of three stains; ninhydrin, potassium permanganate or anisaldehyde. Chromatogpraphic purifications were carried out using a Biotage (Uppsala, Sweden) Isolera One or Biotage SP4 flash purification system using Biotage pre-packed SNAP columns (FCC). Reactions were monitored using an Aglient (Cheshire, U.K.) 1200 series, 6120 quadrupole LC/MS machine and a Merck Chromolith Performance RP-18 HPLC column. Deuterated solvents were from Sigma-Aldrich. 1 H NMR spectra were obtained using a Bruker AVANCE AV400 (400MHz) NMR spectrometer. All signals are described in δ ppm with multiplets being denoted as singlet, doublet, triplet, quartet and multiplet using the abbreviations s, d, t, q, and m respectively. Chemical shifts were referenced using residual solvent peaks with coupling constants, J, reported in hertz (Hz) to an accuracy of 0.5 Hz. To obtain highresolution mass spectrometry data (HR-MS) a Bruker MicroTOF instrument using an ESI source and Time of Flight (TOF) analyser was used. Mass spectrometry data (m/z) are represented as a ratio of mass to charge in Daltons. A Bruker Tensor 27 instrument was used to obtain Fourier transform infrared spectra (FT-IR). Spectroscopic grade solvents and a Perkin Elmer 241 Polarimeter were used to obtain optical rotations. Scheme S1. Compounds 3 and 4 were synthesized via the route shown in Scheme S1. Methyl ((S)-3-(acetylthio)-2-methylpropanoyl)-D-tryptophan (250mg, 0.69 mmol) was dissolved in 1.0M HCl (aq) (2.7ml). The mixture was heated until reflux and stirred overnight. The reaction mixture was allowed to cool to room temperature before being diluted with 10ml H 2 O. The reaction mixture was then extracted with EtOAc (3 x 15ml), after which all organic fractions were collected and dried over MgSO 4 , filtered and concentrated before being purified by FCC eluting with DCM (CH 2 Cl 2 )/(MeOH + 0.1% AcOH), 95:5. The appropriate fractions were collected and concentrated to dryness to give 3 as a slightly yellow oil, several triturations using Et 2 O, produced a white, waxy, amorphous solid (181mg, 0.59mmol, 86%). TOF) calcd for C 15 To round bottom flask containing Methyl ((S)-3-(acetylthio)-2-methylpropanoyl) -Ltryptophanate (250mg, 0.82mmol) was added 1.0M HCl (aq) (2.7ml). The mixture was allowed to stir under reflux overnight after which the reaction mixture was diluted with H 2 O (10ml). The resulting solution was extracted with EtOAc (3 x 15ml). The organic layers were combined, dried over MgSO 4 , filtered and concentrated to dryness before being purified by FCC using an isocratic gradient of DCM/(MeOH + 0.1% AcOH), 95:5. The appropriate fractions were collected and evaporated in vacuo to yield 4 as a clear, slightly yellow oil. Several triturations with Et 2 O, liberated a white, waxy solid (171 mg, 0.56 mmol, 81%). 
Methyl
(4-((1-chloro-4-hydroxyisoquinoline-3-carboxamido)methyl)benzoyl)-Dtryptophanate (86.9 mg, 0.16 mmol) was dissolved in THF (2 ml) before 1.0M aqueous NaOH (0.47 ml) was added. The mixture was then stirred overnight at room temperature before being neutralized with 1.0M aqueous HCl. The resulting solution was extracted with EtOAc (3 x 5 ml) and the organic layers combined, dried over MgSO 4 , filtered and concentrated before being purified by flash column chromatography (95:5, CH 2 Cl 2 /(MeOH + 0.1% AcOH)) to give the desired compound 5 (79.5 mg, 0.15 mmol, 92%). 1 H NMR(CD 3 
SE. 3. Inhibition Assays.
Except where noted, recombinant forms of VIM-2, VIM-5, VIM-1, NDM-1, SPM-1, and BcII, and IMP-1 MBLs were produced in Escherichia coli; assays were carried out as described. 4 The IC 50 values of all the compounds against B1 MBLs including VIM-2, VIM-5 3 , VIM-1, NDM-1, SPM-1, and BcII, and IMP-1 were determined using the same method as described previously. 4 The inhibitory activities of these compounds against CphA (B2 MBL) 5 and L1 (B3 MBL) 6 were determined using meropenem and nitrocefin, respectively. The IC 50 values were determined for compounds showing inhibition >30% at 100 μM. The details regarding enzyme concentrations please see our previous works.
SE. 4. Crystallographic Analyses.
Structures of VIM-5 in complex with inhibitors 1 and 2 were obtained by cocrystallization; Structures of VIM-2:3 and VIM-2:4 were obtained by soaking. Purified VIM-5 proteins were freshly prepared to a concentration of 20.89 mg/mL in crystallization buffer (50 mM HEPES-NaOH, pH 7.5, 100 mM NaCl), followed by adding 1 mM tris(2-carboxyethyl)phosphine (TCEP) and 5 mM inhibitor. The proteininhibitor mixtures were co-crystallized using the sitting drop vapour diffusion method in 96 well 3-subwell Intelliplates® (Art Robbins). The reservoir buffer for growing crystals were from commercially available crystallization conditions (PACT and INDEX). The crystals were cryoprotected by diluting the crystal growth well solution to 25% (v/v) glycerol to make a cryo-solution which was then added to the crystalisation drop 10:1, crystals were harvested in nylon loops and flash-cooled in liquid nitrogen. Data were collected on single crystals in-house or at the Diamond Light Source synchrotron beamlines. Initial phases were obtained by molecular replacement (MR) using PHASER 7 within PHENIX 8 and the structure of VIM-5 (PDB code: 5A87) 3 as a search model. Crystallization of VIM-2 and soaking with 3 or 4 were carried out as previously described. 9, 10 Crystallographic structure refinement was carried out by iterative rounds of model building using Coot 11 and maximum likelihood restrained refinement using PHENIX. Crystallization conditions are in Table S2 , and data collection and refinement statistics are in Table S3 . (Table S3 ).
SE. 5. Microbiological Testing
Test bacteria were clinical isolates of Escherichia coli (a urinary tract isolate kindly provided by Dr Mandy Wootton, Public Health Wales, Cardiff), Enterobacter aerogenes (a paediatric bloodstream isolate) 12 and Klebsiella pneumoniae Ecl8. 13 Subclass B1 β-lactamase genes were cloned alongside their native hybrid integron promoter: bla IMP-1 (sequence as in Genbank accession number AP012280.1) was PCR amplified from a Pseudomonas aeruginosa clinical isolate (from Dr Mark Toleman, Cardiff University) using primers IntpCH1 F-5'-ACCCAGTGGACATAAGCCTG-3' and impR 5'-AGCGAAGTTGATATGTATTGTG-3'. bla VIM-1 (sequence as in accession number GQ422829.1) was amplified from a K. pneumoniae clinical isolates (from Prof Tim Walsh, Cardiff University) using primers IntpCH1 (above) and vimR 5'-TCTGCTACTCGGCGACTGAG-3'. Both amplicons were TA-cloned into pCR2.1-TOPO (Invitrogen) and subcloned using EcoRI into pSU18. 14 Recombinant plasmids, or pSU18 as control, were used to transform the clinical isolates to chloramphenicol resistance via electroporation, as standard for laboratory E. coli strains. MIC analysis was performed using the standard CLSI microtitre assay protocol 15 using Muller-Hinton Broth in the presence or absence of inhibitor or DMSO vehicle (1% (v/v)). Resistance/susceptibility was assigned by reference to CLSI clinical breakpoints. 16 Fig. S1 Binding modes of 1 and 2 as defined by electron density maps. Structures of (a) VIM-5:1 (PDB ID: 5N58) and (b) VIM-5:2 (PDB ID: 5N55) (protein and compound colors and representations as in Fig. 2) with mF o -DF c electron density (OMIT maps) around 1 and 2 (blue mesh, contoured to 3σ) calculated from the final refined model without ligand present.
Supplementary Figures
Fig. S2 Protein-ligand interactions between 1 and 2 and VIM-5 defined using the Discovery Studio
Visualizer. Compounds 1 and 2 display different interactions with the VIM-5 active site residues. The carboxylate of 1 is positioned to make hydrogenbonding and electrostatic interactions with Ser227, Arg228, Thr229, and Ser230, and its isoquinoline is positioned to form π-π stacking interactions with Tyr67 and cation-π interactions with Arg228. The carboxylate of 2 is positioned to form hydrogen bonds with Arg228 and Asn233, and its isoquinoline and indole moieties are positioned to make π-π stacking interactions with Phe61 and Try67, respectively. 
Fig. S11
Comparison of the VIM-5:2 structure (PDB ID: 5N55) with structures of hydrolyzed penicillin (PDB ID: 4EYF) 17 or hydrolyzed cephalosporin (PDB ID: 4RL0) 18 with NDM-1 reveals that 2 binds to VIM-2 via a similar binding mode to that of MBL substrates, e.g. the carboxylate of 2 forms electrostatic interactions with Arg228 (VIM-2), corresponding to equivalent residue Lys224 (NDM-1), which are involved in binding with the substrate carboxylate. Fig. S18 Testing the reversibility of the inhibition. Recovery of enzyme activity after rapid dilution was tested using the published method. 19 VIM-2 at 10 nM (the enzyme concentration equal to 100-fold used in the activity assay) and 3 at 0.55 μM and 4 at 10 μM (i.e. the concentrations of inhibitor equal to 10-fold the IC 50 value) were preincubated (30 min at r.t.). The samples were then rapidly diluted (100 fold) and the enzyme activity was measured. 
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